KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) EBT Margin (2016 - 2025)

Historic EBT Margin for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Q3 2025 value amounting to 19.13%.

  • Alnylam Pharmaceuticals' EBT Margin rose 408300.0% to 19.13% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.21%, marking a year-over-year increase of 141200.0%. This contributed to the annual value of 16.79% for FY2024, which is 69300.0% up from last year.
  • As of Q3 2025, Alnylam Pharmaceuticals' EBT Margin stood at 19.13%, which was up 408300.0% from 4.57% recorded in Q2 2025.
  • Alnylam Pharmaceuticals' EBT Margin's 5-year high stood at 20.08% during Q3 2023, with a 5-year trough of 153.59% in Q3 2022.
  • Its 5-year average for EBT Margin is 63.22%, with a median of 61.79% in 2022.
  • Its EBT Margin has fluctuated over the past 5 years, first skyrocketed by 1736700bps in 2023, then crashed by -1257900bps in 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' EBT Margin (Quarter) stood at 100.68% in 2021, then surged by 39bps to 61.79% in 2022, then surged by 49bps to 31.31% in 2023, then decreased by -4bps to 32.7% in 2024, then soared by 159bps to 19.13% in 2025.
  • Its EBT Margin was 19.13% in Q3 2025, compared to 4.57% in Q2 2025 and 138.65% in Q1 2025.